

Prof. Michael Baum MB, ChB, FRCS, ChM, MD(hon), FRCR(hon)

Short CV

Current position: Professor Emeritus of Surgery and visiting Prof. of Medical Humanities, University College London.

Qualifications

MB ChB Birm 1960

Fellow Royal College Surgeons 1965

ChM (master of surgery) 1972

MD (hon) Gotenburg University 1986

Fellow of the Royal College of Radiology (hon) 1998

Fellow Royal Society of Arts 1998-2004

Previous appointments

Professor of Surgery Kings College London 1980-1990

Director of Cancer Research Campaign, Clinical Trials Centre 1980-1995

Professor of Surgery Royal Marsden Hospital and Institute of Cancer Research
1990-1996

Professor of Surgery University College London (UCL) 1996-2002

Past and present leadership roles.

Chairman of UKCCCR breast cancer sub-committee 1987-1994

President British Oncological Association 1996-1998

Chairman of Council National Institute Medical Humanities 1999- 2001

President 3rd European Breast Cancer Conference 2002

Principle Investigator International ATAC collaboration investigating adjuvant endocrine therapy for early breast cancer. 1996-2003

Chairman medical committee of AVMA (The Association for the Victims of Medical Accidents) 2000- 2005

Chairman of the National Cancer Research Network Psycho-social Oncology Development Group 2003- 2006

Editor in Chief, International Journal of Surgery 2004-2006

Awards

- Skinner Medal – Royal College Radiologists
- Gold Medal- International College of Surgeons
- Ernest Miles Medal – Royal College of Surgeons
- Celebrating Survival Award – San Antonio Breast Cancer Conference 2000
- Miami Breast Cancer conference award 2001 (A biennial award for a life-time achievement in breast cancer research)
- Best of Oncology, American Society Clinical Oncology 2002 (One of four awards given for the best contribution to cancer research over the previous 12 months)
- The William McGuire award, San Antonio, Texas 2002 (Annual award for a life-time achievement in breast cancer research)
- Charles Marie Gros Award of the International Society of Senology (SIS) 2003 (Annual award for a life-time achievement in breast cancer research)
- **St. Gallen award 2007 (biennial prize for excellence in breast cancer research)**

Innovations

- I established the first multi-centre collaborative group for trials of treatment for breast cancer in 1970 and on the back of that the first purpose built clinical trials centre in 1980.

- I established the first nurse counselling service at Kings College Hospital in 1981 and the first psychosocial oncology research team at the same time.
- With my colleague Dr Terry Priestman I developed the first psychometric instrument for measuring quality of life in patients undergoing treatment for cancer (LASA).
- My group were also involved in developing the ethical models for randomised controlled trials and the development of informed consent procedures. This also included a consumer's advisory group. As Vice President of EUSOMA I was in part instrumental in building up EUROPA DONNA and worked closely with this organization as President of the third European Breast Cancer Conference 2002 in Barcelona that led to the Statement of Barcelona on behalf of EUSOMA, EORTC and EUROPA DONNA.
- My group was the first to show the survival advantage of adjuvant tamoxifen, which has contributed to the 30% fall in breast cancer mortality over the last 15 years.
- As a spin off from these trials we were also the first to note the potential of tamoxifen to prevent breast cancer.
- Most recently I have put together the biggest International cancer trials group in history (ATAC), which in record time demonstrated the superiority of Anastrozole to tamoxifen. Anastrozole was endorsed by NICE as the preferred treatment for hormone responsive postmenopausal women with breast cancer in June 2006.
- Alongside this trial of over 9,000 patients we have a subcommittee responsible for collecting and storing archival material for translational research that will relate the response of the aromatase inhibitors to various phenotypes of breast cancer based on steroid and growth factor receptors.
- This trial also contributed 1,000 patients to a sub protocol measuring quality of life chaired by Prof. Lesley Fallowfield.

- Finally my group has developed a novel technique for delivering radiotherapy at the time of surgery which could save the NHS millions of pounds a year and opens up the way for women in the developing world to enjoy the option of retaining their breasts after surgery for early breast cancer. This technique, TARGIT is now in a multinational RCT in the UK, Europe, Australasia and the USA. I remain principle investigator.
(This technique has been filmed for the BBC cancer week and goes out on the 17th May as their grand finale.)

References 2005/2006

Ernst E, Schmidt K, Baum M.

Complementary/Alternative therapies for the treatment of breast cancer. A systematic review of randomized clinical trials and a critique of current terminology.

Breast J. 2006 Nov-Dec;12(6):526-30. Review

Vaidya JS, Baum M, Tobias JS, Massarut S, Wenz F, Murphy O, Hilaris B, Houghton J, Saunders C, Corica T, Roncadin M, Kraus-Tiefenbacher U, Melchaert F, Keshtgar M, Sainsbury R, Douek M, Harrison E, Thompson A, Joseph D.

Targeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boost.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1335-8. Epub 2006 Nov 2.

Baum M, Cassileth BR, Daniel R, Ernst E, Filshie J, Nagel GA, Horneber M, Kohn M, Lejeune S, Maher J, Terje R, Smith WB.

The role of complementary and alternative medicine in the management of early breast cancer: recommendations of the European Society of Mastology

(EUSOMA).

Eur J Cancer. 2006 Aug;42(12):1711-4

Baum M, Ernst E, Lejeune S, Horneber M.

Role of complementary and alternative medicine in the care of patients with breast cancer: report of the European Society of Mastology (EUSOMA) Workshop, Florence, Italy, December 2004.

Eur J Cancer. 2006 Aug;42(12):1702-10

Tobias JS, Vaidya JS, Keshtgar M, Douek M, Metaxas M, Stacey C, Sainsbury R, D'Souza D, Baum M.

Breast-conserving surgery with intra-operative radiotherapy: the right approach for the 21st century?

Clin Oncol (R Coll Radiol). 2006 Apr;18(3):220-8. Review

Buzdar AU, Baum M, Cuzick J.

Letrozole or tamoxifen in early breast cancer.

N Engl J Med. 2006 Apr 6;354(14):1528-30

Baum M.

Ramifications of screening for breast cancer: consent for screening.

BMJ. 2006 Mar 25;332(7543):728

Baum M, Hackshaw A, Houghton J, Rutqvist, Fornander T, Nordenskjold B, Nicolucci A, Sainsbury R; ZIPP International Collaborators Group.

Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study.

Eur J Cancer. 2006 May;42(7):895-904. Epub 2006 Mar 20.

Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M.

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.

Ann Oncol. 2006 May;17(5):818-26

Retsky MW, Hrushesky W, Baum M.

Sociodemographic determinants of cancer treatment health literacy.

Cancer. 2005 Dec 20

Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M.

Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.

J Clin Oncol. 2005 Oct 20;23(30):7512-7.

Baum M.

Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?

Eur J Cancer. 2005 Aug;41(12):1667-77.

Baum M.

Breast cancer survival and the use of HRT.

Breast. 2005 Jun;14(3):178-80

Vaidya JS, Tobias JS, Baum M, Wenz F, Kraus-Tiefenbacher U, D'souza D, Keshtgar M, Massarut S, Hilaris B, Saunders C, Joseph D.

TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation.

Semin Radiat Oncol. 2005 Apr;15(2):84-91

Baum M, Demicheli R, Hrushesky W, Retsky M.

Does surgery unfavourably perturb the "natural history" of early breast cancer by accelerating the appearance of distant metastases?

Eur J Cancer. 2005 Mar;41(4):508-15.

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hocht-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group.

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Lancet. 2005 Jan 1-7;365(9453):60-2.

Baum M. Breast cancer screening comes full circle.

J Natl Cancer Inst. 2004 Oct 20;96(20):1490-1

Baum M & Schipper H. Fast Facts Breast Cancer 3rd Edition, Health Press, London 2005

References 2004:

Baum M. The endocrine management of postmenopausal women with early breast cancer. Breast Cancer. 2004;11(1):15-9.

Baum M Making Amends misses the point.

BMJ. 2004 Feb 14;328(7436):407.

Vaidya JS, Tobias JS, Baum M, Keshtgar M, Joseph D, Wenz F, Houghton J, Saunders C, Corica T, D'Souza D, Sainsbury R, Massarut S, Taylor I, Hilaris B.

Intraoperative radiotherapy for breast cancer.

Lancet Oncol. 2004 Mar;5(3):165-73.

Baum M. Commentary: false premises, false promises and false positives--the case against mammographic screening for breast cancer.

Int J Epidemiol. 2004 Feb;33(1):66-7

Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M, Forbes J, Guastalla JP, Houghton J, Williams N, Howell A, Locker G, MacKey J, Sainsbury R, Tobias J.

Adjuvant use of anastrozole in breast cancer.

J Clin Oncol. 2004 Apr 15;22(8):1524-6

Tobias JS, Vaidya JS, Keshtgar M, D'Souza DP, Baum M.

Reducing radiotherapy dose in early breast cancer: the concept of conformal intraoperative brachytherapy.

Br J Radiol. 2004 Apr;77(916):279-84

Fennessy M, Bates T, MacRae K, Riley D, Houghton J, Baum M.

Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer.

Br J Surg. 2004 Jun;91(6):699-704.

Gray LC, Vaidya JS, Baum M, Badwe RA, Mitra I, Siddiqui T, Wiarda D.

Functional Maps of Metastases from Breast Cancers: Proof of the Principle that Multidimensional Scaling Can Summarize Disease Progression.

World J Surg. 2004 Jun 8

Vaidya JS, Tobias J, Baum M, Keshtgar M, Houghton J, Wenz F, Corica T, Joseph D.

Intraoperative radiotherapy: the debate continues.

Lancet Oncol. 2004 Jun;5(6):339-40

Baum M. Does the act of surgery provoke activation of "latent" metastases in early breast cancer?

Breast Cancer Res. 2004;6(4):160-1.

Baum M. The use and abuse of human tissue: an analysis of the ethical issues raised by the proposed Human Tissue Act.

Med Leg J. 2004;72(Pt 2):67-9

Baum M. Current Status of Aromatase Inhibitors in the Management of Breast Cancer and Critique of the NCIC MA-17 Trial Cancer Control. 2004 Jul-Aug;11(4):217-21.

Jassem J, Buchanan M, Janicke F, Baum M, Cataliotti L, Kyriakides S, Piccart M, Rutgers EJ, Costa A.

The Hamburg statement: the partnership driving the European agenda on breast cancer. Eur J Cancer. 2004 Aug;40(12):1810-1

Baum M & Henderson C. ed. Classic Papers in Breast Disease , Martin Dunitz, London New York, 2004

Key References prior to 2004

The Statement of Barcelona: The future of Breast Cancer Research in Danger.

Baum M, Buchanan M, Baselga J, Cataliotti L, Jassem J, Piccart M

European Journal of Cancer, 2002, 38;2210-2213

The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialist group.

Anastrozole alone or in combination for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

The Lancet 2002; 359: 2131-2139

Baum M, Chaplain M, Anderson A, Douek M, Vaidya JS. Does breast cancer exist in a state of chaos? *Eur J Cancer* 1999; **35**: 886–91.

Schipper H, Turley EA, Baum M. A new biological framework for cancer research. *Lancet* 1996; **348**: 1149–51.

Baum M, Benson JR Current and future roles of adjuvant endocrine therapy in management of early carcinoma of the breast. In Senn HJ, Gelber RD, Goldhirsch A, Thurlimann B, eds. *Recent Results in Cancer Research—Adjuvant Therapy of Breast Cancer*. Heidelberg: Springer, 1996:215–226.

.Controlled trial of tamoxifen as adjuvant agent in management of Early Breast Cancer. Interim analysis at four years by the Nolvadex Adjuvant Trial Organisation. Baum M, Brinkley DM, Dossett JA, et al
The Lancet Feb. 5th, 1983; 257- 261